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Introduction
Depression and depressive symptoms are frequently encoun-
tered in older individuals.1 Depressive symptoms in older popu-
lations, even in the absence of a clinical diagnosis of depression, 
are associated with a 1.5- to 2-fold higher mortality risk.2,3 The 
pathobiology of late-life depression is incompletely understood, 
but it has been suggested that arterial stiffness is involved.4
Arterial stiffness impairs the cushioning function of large ar-
teries, reduces wave reflection and increases pressure and flow 
pulsatility, which transmits distally and damages the microcircu-
lation.5,6 Microvascular damage leads to impaired vasoreactivity 
and cerebral hypoperfusion7 and can manifest itself as cerebral 
small vessel disease, including white matter hyperintensities, 
subcortical infarcts, Virchow–Robin spaces, cerebral micro-
bleeds and cerebral atrophy.8,9 Cerebral small vessel disease, in 
turn, may predispose to depression via disruption of frontal and 
subcortical structures involved in mood regulation.10,11 In ac-
cord ance, previous studies6,12–17 have shown an association be-
tween arterial stiffness and cerebral small vessel disease. The 
studies were conducted in the general population6,12–14,17 (sample 
sizes ranged from 30313 to 1460 individuals14), or in selected clin-
ical populations (e.g., individuals with diabetes [n = 178]15 or 
 hypertension [n = 167]16). Most of these studies, but not all,13 
were cross- sectional by design. Furthermore, recent longitudinal 
data of the Age, Gene/Environment Susceptibility (AGES)- 
Reykjavik study (n = 1949)18 and the Three City (3C) study (n = 
1214)19 have shown that markers of cerebral small vessel disease 
are associated with incident depressive symptoms.
However, only 3 studies4,20,21 have evaluated the association 
between arterial stiffness and depression, and these studies 
yielded inconsistent results. The Rotterdam Study (n = 3704)4 
and a small case–control study (n = 46),20 which both included 
older individuals (mean age of both study samples 72 yr), 
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Background: Arterial stiffness may contribute to depression via cerebral microvascular damage, but evidence for this is scarce. We therefore 
investigated whether arterial stiffness is associated with depressive symptoms and whether cerebral small vessel disease contributes to this 
association. Methods: This cross-sectional study included a subset of participants from the AGES-Reykjavik study second examination 
round, which was conducted from 2007 to 2011. Arterial stiffness (carotid–femoral pulse wave velocity [CFPWV]), depressive symptoms 
(15-item geriatric depression scale [GDS-15]) and cerebral small vessel disease (MRI) were determined. Manifestations of cerebral small ves-
sel disease included higher white matter hyperintensity volume, subcortical infarcts, cerebral microbleeds,  Virchow–Robin spaces and lower to-
tal brain parenchyma volume. Results: We included 2058 participants (mean age 79.6 yr; 59.0% women) in our analyses. Higher CFPWV was 
associated with a higher GDS-15 score, after adjustment for potential confounders (β 0.096, 95% confidence interval [CI] 0.005–0.187). Addi-
tional adjustment for white matter hyperintensity volume or subcortical infarcts attenuated the association between CFPWV and the GDS-15 
score, which became nonsignificant (p > 0.05). Formal mediation tests showed that the attenuating effects of white matter hyperintensity vol-
ume and subcortical infarcts were statistically significant. Virchow–Robin spaces, cerebral microbleeds and cerebral atrophy did not explain the 
association between CFPWV and depressive symptoms. Limitations: Our study was limited by its cross-sectional design, which precludes 
any conclusions about causal mediation. Depressive symptoms were assessed by a self-report questionnaire. Conclusion: Greater arterial 
stiffness is associated with more depressive symptoms; this association is partly accounted for by white matter hyperintensity volume and sub-
cortical infarcts. This study supports the hypothesis that arterial stiffness leads to depression in part via cerebral small vessel disease.
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showed an association between greater arterial stiffness and 
presence of depression. In contrast, the Netherlands Study of 
Depression and Anxiety (NESDA; n = 618) did not find an asso-
ciation between arterial stiffness and depression.21 However, the 
NESDA included a relatively young sample (mean age 47 yr). 
The contribution of arterial stiffness and cerebral small vessel 
disease to depression may be more important in older people. In 
addition, the foregoing studies did not evaluate whether the 
presence of cerebral small vessel disease contributes to the asso-
ciation (if any) between arterial stiffness and depression.
In view of the above findings, we investigated in a large 
population-based cohort of older men and women whether 
arterial stiffness was associated with depressive symptoms 
and whether any such association was explained by manifes-
tations of cerebral small vessel disease, including white matter 
hyperintensities, subcortical infarcts, Virchow–Robin spaces, 
cerebral microbleeds and cerebral atrophy.
Methods
AGES-Reykjavik Study
For the present study, we used cross-sectional data from the 
AGES-Reykjavik Study second examination, which took place 
from 2007 to 2011. The AGES-Reykjavik Study is a population-
based cohort study originating from the Reykjavik Study, as 
described elsewhere.22 It aimed to investigate genetic and en-
vironmental factors and biological mech anisms leading to 
 major clinical and subclinical disorders in old age, including 
those prevalent in neurocognitive, vascular, musculoskeletal, 
body compositional and metabolic symptoms. The AGES-
Reykjavik Study was approved by the National Bioethics 
Committee in Iceland (approval number: VSN-00–063), and by 
the National Institute on Aging Intramural Institutional 
 Review Board. All participants gave written informed consent. 
Briefly, from 2002 to 2006, 5764 surviving participants in the 
Reykjavik Study were  examined. From 2007 to 2011 there was 
a follow-up exam ination of all surviving participants who 
agreed to participate (n = 3316). Reasons for not attending the 
follow-up  examination included death (n = 1039), refusal (n = 
1198) and loss to  follow-up (n = 211). 
Arterial stiffness
We assessed arterial stiffness by determining carotid–femoral 
pulse wave velocity (CFPWV), as previously described.6 
Briefly, after 15–20 min in a supine posture, we measured 
brachial blood pressure and arterial tonometry with an elec-
trocardiogram obtained from the carotid and femoral arteries 
using a custom transducer (Cardiovascular Engineering, 
Inc.).6 Transit distance from the carotid to femoral arteries was 
assessed with body surface measurements from the supraster-
nal notch to the carotid and femoral pulse recording sites. We 
computed CFPWV as the pulse wave transit distance divided 
by the transit time of the pulse wave from the carotid to fem-
oral arteries, with adjustment for parallel transmission of the 
arterial pulse wave in the brachiocephalic artery and aortic 
arch.6 Higher CFPWV indicates greater arterial stiffness.
Depressive symptoms
We assessed depressive symptoms using the 15-item Geriatric 
Depression Scale (GDS-15; score range 0–15).23 Higher GDS-15 
scores indicate the presence of more depressive symptoms. The 
GDS-15 score can be used as a continuous as well as a dichoto-
mous variable.23 In the present study, we used the continuous 
variable as the primary outcome, because this offers the highest 
power to detect associations. In secondary analyses we also 
evaluated associations with dichotomous measures of depres-
sive symptoms, defined as a dichotomous GDS-15 score of 6 or 
higher23 and/or use of antidepressant medication (tricyclic anti-
depressants, selective serotonin reuptake inhibitors, other non-
tricyclics and monoamine oxidase inhibitors), as assessed based 
on medication bottles brought to the clinic. In addition, the asso-
ciation with apathy was evaluated. The following 3 items of the 
GDS-15 score are related to apathy: 1) “Have you dropped 
many of your activities and interests?”; 2) “Do you prefer to stay 
at home, rather than going out and doing new things?”; and 3) 
“Do you feel full of energy?”.24,25 As described previously,24,25 we 
distinguished an apathy subscale that included all apathy items 
(range 0–3; GDS-3A). Presence of apathy was defined as a GDS-
3A score of 2 or 3 versus no apathy (score of 0 or 1).
Brain MRI measures
Image acquisition 
All eligible participants were offered a high-resolution brain 
MRI acquired on the same study-dedicated 1.5 T Signa Twin-
speed scanner (General Electric Medical Systems). The same 
imaging protocol was used as in the first examination of the 
AGES-Reykjavik Study, which is described elsewhere,22,26,27 
and included the following sequences: 3-dimensional spoiled-
gradient recalled T1-weighted, proton density/T2-weighted 
fast spin-echo, fluid-attenuated inversion recovery (FLAIR) 
and T2*-weighted gradient-echo type echo-planar image 
(GRE-EPI). All images were acquired to give full brain cover-
age, with slices angled parallel to the anterior commissure– 
posterior commissure line in order to give reproducible image 
views in the oblique–axial plane.
Image analysis 
We evaluated several manifestations of cerebral small vessel 
disease. White matter hyperintensity volume (WMHV) and 
 total brain parenchyma volume (an indicator of cerebral atro-
phy) were computed automatically with a previously de-
scribed image analysis pipeline28 and were calculated as the 
percentage of total intracranial volume (ICV). We considered 
lower total brain parenchyma volume to be a manifestation of 
cerebral small vessel disease, as cerebral small vessel disease 
may contribute to generalized loss of brain parenchyma via, 
among others, microinfarcts29 and loss of white matter integ-
rity.30 Subcortical infarcts were evaluated as described previ-
ously26 and defined as a brain parenchyma defect with a 
 minimum diam eter of 4 mm, not extending into the cortex, 
with a signal intensity equal to cerebrospinal fluid on all pulse 
sequences (i.e., T2-weighted, proton density–weighted and 
FLAIR) and surrounded by an area of high signal intensity on 
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FLAIR images. Parenchymal defects in the subcortical area 
with evidence of hemosiderin on the T2*-weighted GRE-EPI 
scan were labelled as resorbed hematomas and were excluded 
from the definition of subcortical infarcts. In addition, Virchow–
Robin spaces were evaluated separately and defined as defects 
in the subcortical area without a rim or area of high signal inten-
sity on FLAIR and without evidence of hemosiderin on the T2*-
weighted GRE-EPI scan. We considered the presence of 
 Virchow–Robin spaces to be a manifestation of cerebral small 
vessel disease, as they are associated with endothelial dysfunc-
tion, which may play a role in the pathogenesis of cerebral small 
vessel disease.8 Cerebral microbleeds were defined as a focal 
area of signal void within the brain parenchyma visible on T2*-
weighted GRE-EPI scans and were identified as described 
 previously.27
Confounding variables
Education (categorized into primary, secondary and college/
university education) was measured at baseline. All other 
confounding variables were measured during the second ex-
amination of the AGES-Reykjavik Study. Smoking history 
(categorized into none, former and current smoker) was as-
sessed using a questionnaire. Use of antihypertensive medi-
cation was assessed using a questionnaire and by assessing 
medication bottles brought to the clinic. We evaluated bra-
chial artery mean arterial pressure and heart rate during 
the  arterial stiffness measurements by using a computer- 
controlled mano meter and an electrocardiogram, respect-
ively.6 Gait speed, a measure of physical performance,31 was 
determined as the time in seconds needed to walk 6 metres 
at a usual pace. Diabetes mellitus was defined as a self- 
reported doctor’s diagnosis of diabetes, use of blood 
 glucose–lowering drugs or fasting blood glucose level of 
7.0  mmol/L or higher. The coronary calcium score (cat-
egorized into sex-specific quartiles), a measure of athero-
scler osis, was based on computed tomography scan.32 The 
Digit Symbol Substitution Test (DSST), a measure of cogni-
tive function, was also administered.22
Statistical analysis
We performed our statistical analyses using PASW statistics 
version 21. We inverse-transformed CFPWV to reduce het-
eroscedasticity and multiplied it by –1000 to restore directional-
ity and to convert the units to milliseconds per metre. In addi-
tion, CFPWV was entered as a sex-specific Z score in all 
models. We logarithmically transformed WMHV to normalize 
the skewed distribution, and we entered WMHV and lower 
 total brain parenchyma volume as Z scores in all models.
Linear and logistic regression analyses were used to esti-
mate the association between CFPWV, the GDS-15 score and 
markers of cerebral small vessel disease. Models were ad-
justed for the following potential confounders (selected based 
on previous literature and knowledge): age, sex, education 
level, smoking, DSST, gait speed, BMI, diabetes, mean arter-
ial pressure, heart rate, coronary calcium score and the use of 
antihypertensive medication. Associations are reported as 
unstandardized regression coefficients with corresponding 
95% confidence intervals (CI).
We used mediation analysis33 to test the hypothesis that 
manifestations of cerebral small vessel disease (that is, higher 
WMHV, presence of subcortical infarcts, Virchow–Robin 
spaces, cerebral microbleeds and lower total brain paren-
chyma volume) are on the potential causal pathway of the 
association between arterial stiffness and depressive symp-
toms. The model quantifies the degree to which a variable 
statistically moderates the association of a dependent vari-
able with an independent variable. We used bootstrapping 
(10 000 samples) to calculate bias-corrected 95% CIs of the ex-
plained effects using the PROCESS statistical package for 
PASW statistics.33 The magnitude of the explained effect was 
calculated as a percentage of the total direct effect.
We performed the following secondary analyses. Logistic 
analysis was performed to evaluate the association between 
CFPWV and a dichotomous measure of depressive symp-
toms. It has been suggested24 that cerebral small vessel disease 
may be associated with, in particular, apathy-related or 
 motivation-related symptoms of depression, but not with 
mood-related symptoms. Therefore, we performed logistic re-
gression analyses to evaluate the association between  CFPWV 
and individual apathy items of the GDS-15 score as the out-
come. To minimize the potential confounding effect of stroke, 
we repeated the analyses after excluding individuals with a 
clinical diagnosis of stroke. In addition, it has been suggested 
that deep or infratentorial cerebral microbleeds (i.e., micro-
bleeds located in the basal ganglia, thalamus, brainstem and 
cerebellum) are more closely associated with vascular disease, 
whereas lobar microbleeds might be more closely associated 
with amyloid angiopathy.34 Therefore, analyses were repeated 
with presence of deep cerebral microbleeds only, instead of 
the presence of any microbleed.  Finally, we investigated 
whether the association between arterial stiffness and depres-
sive symptoms differed by sex by adding interaction terms 
between arterial stiffness and sex to the fully adjusted models. 
We found no such interaction (p = 0.57) and, therefore, all re-
sults are presented for men and women combined.
Results
Of the 3316 participants of the second examination of the 
AGES-Reykjavik Study, 648 had missing brain MRI data, 
419 had missing data on arterial tonometry and 77 had miss-
ing data on depressive symptoms. Reasons for missing MRI 
data were contraindications (n = 272), refusal/nonattendance 
(n = 337) or technical reasons (no qualitatively acceptable MRI 
data available for all necessary sequences; n = 39). Missing 
data on tonometry was due to logistical or technical reasons. 
Of the remaining 2172 participants, we excluded those with a 
diagnosis of dementia (all subtypes; n = 114), which was diag-
nosed according to international guidelines35 by a panel that 
included a geriatrician, a neurologist, a neuropsychologist 
and a neuroradiologist, as described elsewhere.22 Excluded 
participants were more likely to be older (81.2 yr v. 76.6 yr), 
less educated (primary school or less: 23.6% v. 18.9%) and to 
have a higher body mass index (BMI; 27.3 v. 26.5) and to have 
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higher prevalences of diabetes (17.6% v. 11.6%) and stroke 
(11.5% v. 8.2%; all p < 0.05). 
The final study sample for the present analysis consisted of 
2058 participants. Characteristics of the study population are 
described in Table 1. Briefly, participants had a mean age of 
79.6 years, and 59.0% were women. Median CFPWV was 
12.5 m/s (interquartile range [IQR] 10.4–15.7). The median 
GDS-15 score was 2 (IQR 1–3); 109 (5.3%) participants had a 
GDS-15 score of 6 or higher. A total of 294 (14.3%) participants 
used antidepressant medication.
Association between arterial stiffness and depressive  symptoms
Higher CFPWV (per standard deviation [SD]) was significantly 
associated with a higher GDS-15 score (b 0.096, 95% CI 0.005–
0.187, explained variance by CFPWV R2 = 0.003) after adjust-
ment for confounders but without adjustment for any of the 
potential mediators.
Contribution of manifestations of cerebral small vessel disease 
to the association between arterial stiffness and  depressive 
symptoms
Higher CFPWV was significantly associated with a higher 
WMHV, and higher WMHV was significantly associated with 
a higher GDS-15 score (Fig. 1A). When we adjusted the associ-
ation between CFPWV and the GDS-15 score for WMHV, the 
association was attenuated and was no longer statistically sig-
nificant (Fig. 1A). The explained effect by WMHV was signifi-
cant and was 6% of the total direct effect between CFPWV 
and the GDS-15 score (Table 2).
Similarly, higher CFPWV was significantly associated with 
the presence of subcortical infarcts (Fig. 1B), and the presence 
of subcortical infarcts was significantly associated with a 
higher GDS-15 score (Fig. 1B). When we adjusted the associ-
ation between CFPWV and the GDS-15 score for subcortical 
infarcts, the association was attenuated and was no longer 
significant (Fig. 1B). The effect of subcortical infarcts was sig-
nificant and was 9% of the total direct effect between CFPWV 
and the GDS-15 score (Table 2).
When WMHV and subcortical infarcts were entered simulta-
neously into the mediation model, they explained 12% of the 
total direct effect between CFPWV and the GDS-15 score.
In contrast, Virchow–Robin spaces, cerebral microbleeds 
and total brain parenchyma volume did not attenuate the 
association between CFPWV and the GDS-15 score (Table 2 
and Appendix 1, Fig. S1, available at jpn.ca). Higher CFPWV 
was associated with the presence of Virchow–Robin spaces 
and cerebral microbleeds, but these lesions were not associ-
ated with depressive symptoms. In addition, lower total 
brain parenchyma volume was significantly associated with 
more depressive symptoms, but CFPWV was not associated 
with lower total brain parenchyma volume.
Secondary analyses
We found that CFPWV was not significantly associated with a 
dichotomous measure of depressive symptoms (i.e., GDS-15 
score ≥ 6) or use of antidepressant medication (n = 336) (odds 
ratio [OR] 1.10, 95% CI 0.96–1.26). In addition, CFPWV was not 
significantly associated with a presence of depressive symp-
toms, defined as a GDS-15 score of 6 or higher, irrespective of 
the use of antidepressant medication (n = 109) (OR 1.02, 95% CI 
0.81–1.29). We found that CFPWV was not associated with apa-
thy (i.e., GDS-3A score of 2 or 3) after adjustment for all poten-
tial confounders (OR 1.07, 95% CI 0.96–1.19). After the exclu-
sion of individuals with stroke (n = 223), the explained effects 
by WMHV and subcortical infarcts did not materially change 
(Appendix 1, Table S1). Finally, when we repeated the analyses 
with the presence of deep or cerebral microbleeds instead of the 
presence of any microbleed, results did not materially change 
(data not shown).
Discussion
We evaluated whether arterial stiffness is associated with de-
pressive symptoms and whether any such association can be ex-
plained by cerebral small vessel disease. We had 2 main find-
ings. First, arterial stiffness, as determined by CFPWV, was 
independently associated with a higher level of depressive 
symptoms. Second, this association was explained in part (12%) 
by WMHV and subcortical infarcts, but not by  Virchow–Robin 
spaces, cerebral microbleeds and cerebral atrophy.
These data are consistent with the hypothesis that arterial 
stiffness increases the risk of depressive symptoms in part via 
Table 1: Characteristics of the study population (n = 2058)
Characteristic
Mean ± SD, median [IQR]  
or no. (%)
General characteristics
Age, yr 79.6 ± 4.6
Female sex 1214 (59.0)
Smoking status
Nonsmoker 897 (43.6)
Former 983 (47.8)
Current 177 (8.6)
Education
Primary or less 398 (18.9)
Secondary 1084 (52.7)
College/university 584 (28.4)
Digit Symbol Substitution Test score 30 ± 10
Body mass index 26.5 ± 3.9
Diabetes 239 (11.6)
Stroke 169 (8.2)
Systolic blood pressure, mm Hg 145 ± 21
Diastolic blood pressure, mm Hg 70 ± 11
Use of antihypertensive medication 1473 (71.6)
Brain MRI measures
White matter hyperintensity volume, mL 15 [8–28]
Subcortical infarcts 202 (9.8)
Virchow–Robin spaces 364 (17.7)
Cerebral microbleeds 603 (29.3)
Total brain parenchyma volume, mL 1067 ± 99
IQR = interquartile range; SD = standard deviation.
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cerebral microvascular damage. Arterial stiffness may cause 
microvascular damage via an increased pulsatile load on the 
microcirculation.36,37 This increased load causes direct micro-
vascular damage and induces a microvascular remodelling 
response. Microvascular remodelling initially serves to limit 
the penetration of the pulsatile pressure load into the microcir-
culatory system by raising vascular resistance. Yet, this protec-
tive response may ultimately become unfavourable, leading to 
impaired vasoreactivity, cerebral hypoperfusion and micro-
vascular ischemia.7,36 Ischemia may damage frontal and sub-
cortical structures or their connecting pathways involved in 
mood regulation and, hence, may lead to depression.7,10,11
Previous studies have shown associations of CFPWV or local 
carotid stiffness with various manifestations of cerebral small 
vessel disease, including WMHV6,12,17 and subcortical or lacu-
nar infarcts.6,12,17 In addition, previous studies have shown an 
association between depression and WMHV19,38 and lacunar in-
farcts.38,39 Furthermore, a population-based study4 has shown 
that higher CFPWV and local carotid stiffness were associated 
with depression. The present study shows that the association 
between arterial stiffness and depressive symptoms is in part 
explained by cerebral small vessel lesions and thereby provides 
additional evidence consistent with the role of arterial stiffness 
in modulating the emergence of late-life depressive symptoms.
However, a relatively large part of the association between 
arterial stiffness and depressive symptoms remained 
unexplained after taking into account the effects of WMHV and 
subcortical infarcts. This remaining association may be due to 
vascular brain lesions not (directly) captured in the MRI scans 
(e.g., microinfarcts and loss of white matter integrity) that we 
did not incorporate into the analyses. In addition, it is possible 
that only a subset of the participants who scored poorly on the 
GDS-15 have vascular-related disease. Finally, although we 
adjusted for a large series of potential confounders, we cannot 
exclude the possibility of residual confounding.
Cerebral small vessel disease encompasses different lesions 
found on neuroimaging.6,8 Specific clinical consequences of 
each lesion type and their location are, however, not completely 
understood. In the present study, WMHV and subcortical in-
farcts explained a part of the association between arterial stiff-
ness and depressive symptoms, whereas Virchow– Robin 
spaces, cerebral microbleeds and cerebral atrophy did not. 
Although higher CFPWV was associated with presence of 
Virchow–Robin spaces and cerebral microbleeds, these lesions 
were not associated with depressive symptoms. It is possible 
that Virchow–Robin spaces and cerebral microbleeds play a 
role early in the pathogenesis of cerebral small vessel disease,40 
whereas WMHs and subcortical infarcts represent more ad-
vanced disease states. In addition, although lower brain paren-
chyma volume was associated with a higher level of depressive 
symptoms, brain parenchyma volume was not associated with 
CFPWV. Cerebral atrophy is strongly determined by factors 
other than vascular disease, particularly the process of neuro-
degeneration.8 This may have resulted in an underestimation 
of the association between CFPWV and brain parenchyma 
volume in the older population included in this study.
Fig. 1: Association between carotid–femoral pulse wave velocity (CFPWV) and the 15-item Geriatric Depression Scale (GDS-15) score 
and the explained effects of this association by (A) white matter hyperintensity volume and (B) subcortical infarcts. Solid lines indicate sig-
nificant associations; dashed lines indicate nonsignificant associations. Associations are given as regression coefficients (β) or odds ratios 
(ORs), and corresponding 95% confidence intervals (CIs). The CFPWV and white matter hyperintensity volume are indicated per higher 
standard deviation (SD). All associations are adjusted for age, sex, education level, smoking, digit symbol substitution test score, gait 
speed, body mass index, diabetes, mean arterial pressure, heart rate, coronary calcium score and use of antihypertensive medication.
 
Panel B 
Panel A 
 
Adjusted for potential confounders: 
 β 0.096 (0.005 to 0.187) 
GDS-15 score CFPWV  
β 0.050 (0.002 to 0.097)  β 0.125 (0.041 to 0.208) 
White matter 
hyperintensity 
volume 
Additionally adjusted for white matter hyperintensity volume:  
β 0.090 (–0.001 to 0.181) 
Adjusted for potential confounders:  
 β 0.096 (0.005 to 0.187) 
GDS-15 score CFPWV  
OR 1.27 (1.06 to 1.52) 
Subcortical 
infarcts 
Additionally adjusted for subcortical infarcts: 
β 0.088 (–0.003 to 0.179) 
β 0.455 (0.188 to 0.722) 
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Strengths of the present study are the large population-based 
sample of older individuals, the comprehensive brain MRI as-
sessment of various manifestations of cerebral small vessel dis-
ease and the extensive characterization of participants, which 
enabled us to adjust for a series of potential confounders.
In view of global aging and the increased prevalence of ar-
terial stiffness with age, efforts at favourably influencing arter-
ial stiffness may have significant public health implications for 
preventing vascular-related depression. Arterial stiffness may 
be favourably influenced by lifestyle modifications, such as 
weight loss, increased (habitual) physical activity and dietary 
modifications (e.g., low consumption of sodium). In addition, 
drugs, such as angiotensin receptor-2 agonists (e.g., compound 
21), may lower arterial stiffness, possibly beyond any blood-
pressure lowering effects.41
Limitations
Our study has some limitations. First, the cross-sectional design 
precludes any conclusions about a temporal association between 
arterial stiffness, cerebral small vessel disease and depressive 
symptoms. The evidence provided in the present study is, there-
fore, necessarily circumstantial. Nevertheless, it provides impor-
tant support for more definitive investigations. It has been sug-
gested that the association between depression and arterial 
stiffness may be bidirectional.21 Depressive symptoms may lead 
to arterial stiffness via multiple mechanisms, including inflam-
mation, endothelial dysfunction and unfavourable lifestyle hab-
its.42–44 Indeed, a recent small clinical trial showed that treatment 
of depression may decrease arterial stiffness.45 Further longitud-
inal studies are needed to clarify this issue. Furthermore, the as-
sociations between arterial stiffness,  cerebral small vessel disease 
and depressive symptoms may reflect more direct measures of 
common underlying mechanisms (e.g., inflammation and oxida-
tive stress). Second, depressive symptoms were assessed using a 
self-report questionnaire rather than a structured interview. 
Therefore, no information was available on the presence of a 
major depressive disorder. Third, it is possible that death or at-
trition between the AGES-1 and -2 studies resulted in a dispro-
portional loss of people who were likely at high risk for depres-
sion. The associations between arterial stiffness, cerebral small 
vessel diseaes and depression found in the present study sample 
may be biased if associations substantively differed in people 
who were lost to  follow-up. We consider this biased attrition un-
likely, in which case the loss of the individuals reduces our 
power to detect existing associations. Fourth, the level and se-
verity of depressive symptoms in this study was relatively low 
compared with depression rates in other European countries,46 
but our rates are consistent with those found in a previous study 
conducted in Iceland.46 This low symptomatology may, how-
ever, have reduced the effect sizes and sensitivity to detect asso-
ciations. This may explain why an association was found be-
tween arterial stiffness and a continuous depressive symptom 
score, but not with a dichotomous depression score. Analyses 
with a continuous outcome, in general, have higher statistical 
power than analyses with a dichotomous outcome. Finally, a 
 relatively high number of individuals used antidepressant med-
ication (14.3%) compared with the number of individuals with a 
GDS-15 score of 6 or higher (5.3%). Misclassification of the di-
chotomous depression score may have occurred because antide-
pressant medication is also prescribed for other reasons, and this 
may have led to an underestimation of the association between 
arterial stiffness and the dichotomous depression score.
Conclusion
The present study shows an association between greater ar-
terial stiffness and more depressive symptoms in a general 
older population, and this association is in part explained by 
WMHV and subcortical infarcts.
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